Horizon Therapeutics Plc Profit Margin

The latest profit margin for HZNP is 12.02% as of June 2023. That compares with 20.06% in the prior-year period — down 40.1% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Horizon Therapeutics Plc's historical trend and sector peers before judging valuation or financial health.

Over the past year, HZNP's profit margin moved from 20.06% to 12.02% — a 40.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Horizon Therapeutics Plc's valuation or profitability profile.

Against Healthcare companies, HZNP currently prints 12.02% for profit margin, while the sector average sits near 14.34%. That is roughly 16.2% below the sector mean. Large gaps often invite a closer look at Horizon Therapeutics Plc's growth, margins, and balance sheet.

Profit Margin shows how effectively Horizon Therapeutics Plc converts resources into returns. At 12.02%, HZNP may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 20.06% in the prior-year period — down 40.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting HZNP's profit margin (12.02%), review year-over-year change from 20.06%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.